197 related articles for article (PubMed ID: 34224197)
1. Identification of Novel Histone Deacetylase 6-Selective Inhibitors Bearing 3,3,3-Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group.
Kurohara T; Tanaka K; Takahashi D; Ueda S; Yamashita Y; Takada Y; Takeshima H; Yu S; Itoh Y; Hase K; Suzuki T
Chembiochem; 2021 Nov; 22(22):3158-3163. PubMed ID: 34224197
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group.
Linciano P; Pinzi L; Belluti S; Chianese U; Benedetti R; Moi D; Altucci L; Franchini S; Imbriano C; Sorbi C; Rastelli G
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2080-2086. PubMed ID: 34583596
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors.
Xu Y; Tang H; Xu Y; Guo J; Zhao X; Meng Q; Xiao J
Molecules; 2022 May; 27(10):. PubMed ID: 35630812
[TBL] [Abstract][Full Text] [Related]
4. Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors.
Tavares MT; Kozikowski AP; Shen S
Eur J Med Chem; 2021 Jan; 209():112887. PubMed ID: 33035922
[TBL] [Abstract][Full Text] [Related]
5. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
6. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
Ruzic D; Djokovic N; Nikolic K
Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
[TBL] [Abstract][Full Text] [Related]
7. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
9. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
10. Discovery of specific HDAC6 inhibitor with anti-metastatic effects in pancreatic cancer cells through virtual screening and biological evaluation.
Song H; Niu X; Quan J; Li Y; Yuan L; Wang J; Ma C; Ma E
Bioorg Chem; 2020 Apr; 97():103679. PubMed ID: 32120077
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.
Porter NJ; Osko JD; Diedrich D; Kurz T; Hooker JM; Hansen FK; Christianson DW
J Med Chem; 2018 Sep; 61(17):8054-8060. PubMed ID: 30118224
[TBL] [Abstract][Full Text] [Related]
12. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
13. Metal-Free Direct Amidation of Naphthoquinones Using Hydroxamic Acids as an Amide Source: Application in the Synthesis of an HDAC6 Inhibitor.
Zhang C; Chou CJ
Org Lett; 2016 Nov; 18(21):5512-5515. PubMed ID: 27759399
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
15. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays.
Uba AI; Hryb M; Singh M; Bui-Linh C; Tran A; Atienza J; Misbah S; Mou X; Wu C
Life Sci; 2024 Feb; 338():122395. PubMed ID: 38181853
[TBL] [Abstract][Full Text] [Related]
17. Combined Ligand and Fragment-based Drug Design of Selective Histone Deacetylase - 6 Inhibitors.
Ruzic D; Petkovic M; Agbaba D; Ganesan A; Nikolic K
Mol Inform; 2019 May; 38(5):e1800083. PubMed ID: 30632697
[TBL] [Abstract][Full Text] [Related]
18. Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.
Leonhardt M; Sellmer A; Krämer OH; Dove S; Elz S; Kraus B; Beyer M; Mahboobi S
Eur J Med Chem; 2018 May; 152():329-357. PubMed ID: 29738953
[TBL] [Abstract][Full Text] [Related]
19. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
[TBL] [Abstract][Full Text] [Related]
20. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]